TAT(SZ:002433)2014-04-25 16:00Financial Performance - The company's operating revenue for Q1 2014 was CNY 172,093,860.73, representing a 54.13% increase compared to CNY 111,657,434.47 in the same period last year[8]. - The net profit attributable to shareholders for Q1 2014 was CNY 30,158,028.25, a 50.57% increase from CNY 20,029,890.28 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was CNY 29,086,622.42, reflecting a 49.45% increase compared to CNY 19,462,613.37 in the previous year[8]. - The weighted average return on equity improved to 1.52%, up from 1.08% in the previous year[8]. - The net profit attributable to shareholders for the first half of 2014 is expected to increase by 45% to 55%, with a range of CNY 57,640,400 to CNY 61,615,600[26]. - The growth in sales of cardiovascular and reproductive health drugs, as well as ginseng and traditional Chinese medicine products, contributed to the expected profit increase[26]. Cash Flow and Expenses - The company's cash flow from operating activities showed a net outflow of CNY 18,191,191.96, an improvement of 17.32% from a net outflow of CNY 22,002,842.55 in the same period last year[8]. - Cash received from sales of goods and services increased by CNY 47,184,838.94, up 32.36% year-on-year, attributed to sales growth and improved cash collection[18]. - Cash paid for purchasing goods and services rose by CNY 40,154,799.44, an increase of 31.01%, due to higher procurement during the reporting period[18]. - Cash paid to employees increased by CNY 2,055,908.68, up 31.91%, primarily due to increased social insurance contributions for employees[18]. - Cash paid for acquiring fixed assets, intangible assets, and other long-term assets decreased by CNY 56,479,374.78, down 51.28%, mainly due to reduced investments[18]. - Cash inflow from financing activities increased by CNY 116,000,000.00, up 1160.00%, due to increased bank borrowings[23]. - Cash outflow from financing activities rose by CNY 79,914,218.31, an increase of 775.20%, mainly due to repayment of bank loans and increased interest[27]. Assets and Shareholder Information - The total assets at the end of the reporting period were CNY 2,584,094,726.95, a 1.11% increase from CNY 2,555,749,804.33 at the end of the previous year[8]. - The number of shareholders at the end of the reporting period was 24,390, with the top ten shareholders holding a combined 56.56% of the shares[11]. Government Subsidies and Non-Operating Income - The company received government subsidies totaling CNY 1,254,467.49 during the reporting period, contributing to an 87.86% increase in non-operating income[9][17]. Financial Expenses - The company reported a significant increase in financial expenses, which rose by 1577.49% due to increased bank borrowings during the reporting period[17]. Minority Shareholder Profit - Minority shareholder profit increased by CNY 650,398.85, a growth of 47.72% compared to the same period in 2013, mainly due to the increase in total profit of Hongxing Group[18]. Securities Investments - No securities investments were held at the beginning or end of the reporting period, with a total value of 0.00 yuan[27]. - The report indicates no gains or losses from securities investments during the reporting period[27]. - The company did not disclose any holdings in other listed companies[29].